3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(dimethylphosphoryloxymethyl)phenyl]pyridin-2-amine | 1394345-97-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(dimethylphosphoryloxymethyl)phenyl]pyridin-2-amine
• 英文别名: 3-[1-(2,6-Dichloro-3-fluoro-phenyl)ethoxy]-5-[4-(dimethylphosphoryloxymethyl)phenyl]pyridin-2-amine
• CAS: 1394345-97-1
• 化学式: C₂₂H₂₂Cl₂FN₂O₃P
• 分子量: 483.306
• InChiKey: WZKAQBWTQQDRKP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  74.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  (4-{6-amino-5-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]pyridin-3-yl}phenyl)methanol 、 二甲基氯氧化磷 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 1.5h， 以11%的产率得到3-[1-(2,6-dichloro-3-fluorophenyl)ethoxy]-5-[4-(dimethylphosphoryloxymethyl)phenyl]pyridin-2-amine
  参考文献：
  名称：

  PHOSPHORUS CONTAINING COMPOUNDS AS PROTEIN KINASE INHIBITORS

  摘要：

  本发明涉及由式(I)表示的化合物，可调节蛋白激酶的活性。该发明还涉及含有式(I)化合物的组合物，以及用于合成和使用此类化合物以预防或治疗ALK或cMet介导的疾病或状况的方法。

  公开号：

  US20120220551A1

文献信息

• Phosphorus containing compounds as protein kinase inhibitors
  申请人：Hu Baihua

  公开号：US08951993B2

  公开（公告）日：2015-02-10

  The present invention relates to compounds represented by formula (I), which can modulate the activity of protein kinases. The invention also relates to a composition containing a compound of formula (I), and a method for synthesizing and using such compound for preventing or treating ALK or cMet mediated disorders or conditions.

  本发明涉及由式(I)表示的化合物，其可以调节蛋白激酶的活性。本发明还涉及包含式(I)化合物的组合物以及用于预防或治疗ALK或cMet介导的疾病或病症的合成和使用该化合物的方法。
• EP3125920B1
  申请人：——

  公开号：EP3125920B1

  公开（公告）日：2020-12-23
• COMBINATION OF ANALOGS OR DERIVATIVES OF DIANHYDROGALACTITOL WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT CANCER
  申请人：Delmar Pharmaceuticals, Inc.

  公开号：EP3294284A1

  公开（公告）日：2018-03-21
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES
  申请人：Del Mar Pharmaceuticals

  公开号：US20160008316A1

  公开（公告）日：2016-01-14

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.
• USE OF DIANHYDROGALACTITOL AND ANALOGS OR DERIVATIVES THEREOF IN COMBINATION WITH PLATINUM-CONTAINING ANTINEOPLASTIC AGENTS TO TREAT NON-SMALL-CELL CARCINOMA OF THE LUNG AND BRAIN METASTASES
  申请人：BACHA Jeffrey

  公开号：US20180140571A1

  公开（公告）日：2018-05-24

  The use of dianhydrogalactitol provides a novel therapeutic modality for the treatment of non-small-cell lung carcinoma (NSCLC) and ovarian cancer, as well as other types of malignancy, including brain metastases of NSCLC. Dianhydrogalactitol acts as an alkylating agent on DNA that creates N 7 methylation. Dianhydrogalactitol is effective in suppressing the growth of cancer stem cells and is active against tumors that are refractory to temozolomide, cisplatin, and tyrosine kinase inhibitors; the drug acts independently of the MGMT repair mechanism. Dianhydrogalactitol can be used together with other anti-neoplastic agents and can possess additive or super-additive effects.